Medication use and indicators of poor asthma control in patients with and without allergies

2019 ◽  
Vol 40 (4) ◽  
pp. 221-229
Author(s):  
Patrick W. Sullivan ◽  
Miguel J. Lanz ◽  
Vahram H. Ghushchyan ◽  
Abhishek Kavati ◽  
Jason LeCocq ◽  
...  
Keyword(s):  
Asthma Control ◽  
Medication Use

scholarly journals Asthma Control and Asthma Medication Use among Swedish Elite Endurance Athletes

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Hampus Persson ◽  
Anne Lindberg ◽  
Nikolai Stenfors
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Reference Group ◽  
Medication Use ◽  
Study Groups ◽  
Asthma Medication ◽  
Endurance Athletes ◽  
Act Scores ◽  
Asthma Control Test ◽  
Long Acting

Background. Asthma is common in elite athletes. In this study, we examined the use of asthma medication and asthma control in endurance athletes in Sweden and compared the findings with those in a reference group of patients with asthma. Methods. The Asthma Control Test (ACT) and a questionnaire on asthma, respiratory symptoms, and medication use were posted to endurance athletes n=711 and the reference group of patients with asthma n=1026. Four hundred and sixty-nine athletes (66%) responded, of whom 141 (20%) reported physician-diagnosed asthma. In the reference group, 397 (39%) responded. Results. Seventy-seven percent of the athletes with asthma reported using asthma medication during the previous year; 39% used short/long-acting β2-agonists, 31% used inhaled corticosteroids, and 31% used both daily. According to the ACT scores, 19%, 24%, and 58% of athletes with asthma had uncontrolled, partially controlled, or well-controlled asthma, respectively. After adjustment, there was no difference in ACT scores or daily use of asthma medication between the study groups. Conclusions. Many endurance athletes had uncontrolled or partially controlled asthma, and one-third used inhaled corticosteroids and long-acting β2-agonists daily. Their adjusted ACT scores and use of asthma medication were similar to the values in the reference population.

scholarly journals Reduced medication use and improved pulmonary function with supplements containing vegetable and fruit concentrate, fish oil and probiotics in asthmatic school children: a randomised controlled trial

2012 ◽  
Vol 110 (1) ◽  
pp. 145-155 ◽  
Author(s):  
Shu-Chen Lee ◽  
Yao-Hsu Yang ◽  
Shao-Yuan Chuang ◽  
Shih-Yi Huang ◽  
Wen-Harn Pan
Keyword(s):  
Pulmonary Function ◽  
Fish Oil ◽  
Asthma Control ◽  
Childhood Asthma ◽  
Test Score ◽  
Medication Use ◽  
Control Test ◽  
Asthma Control Test ◽  
Asthmatic Children ◽  
Supplement Group

Dietary pattern changes may be one of the key factors associated with increasing asthma prevalence. Observational studies have found negative associations between fruit, vegetable and fish consumption and risk of asthma. Experimental studies have also shown that probiotics can modulate the immune system. However, each dietary component exhibits a modest effect. The objective of the present study was to investigate the joint effect of multiple beneficial dietary components on asthma. We designed a 16-week school-based double-blind placebo-controlled randomised trial. The supplement group received fruit plus vegetable concentrate, fish oil and probiotics (FVFP supplement), while the control group received placebos. A total of 192 asthmatic children aged 10–12 years were recruited from elementary schools in metropolitan Taipei. Pulmonary function, medication usage, Paediatric Asthma Quality of Life Questionnaire (PAQLQ) score and the Childhood Asthma Control Test score were evaluated at baseline, and at weeks 8 and 16. Compared with the placebo group, the supplement group showed significant improvement in pulmonary function parameters (91 v. 178 ml for forced vital capacity (FVC), 40 v. 107 ml for forced expiratory volume in 1 s (FEV1) and 1·6 v. 4·8 % for FEV1:FVC ratio; all P values < 0·01) and had a significantly reduced proportion of those using short-acting inhaled bronchodilators and inhaled corticosteroids. However, the PAQLQ score and the Childhood Asthma Control Test score were not significantly different between the two groups, possibly because the majority of the children were treated routinely. FVFP supplements reduced medication use and improved pulmonary function in asthmatic children. The present study supports an adjuvant intervention with a combination of fruit, vegetable, fish and probiotic foods.

scholarly journals The CASE Survey: Patient and Physician Perceptions Regarding Asthma Medication Use and Associated Oropharyngeal Symptoms

2008 ◽  
Vol 15 (1) ◽  
pp. 27-32 ◽  
Author(s):  
J Mark FitzGerald ◽  
Charles KN Chan ◽  
Martin C Holroyde ◽  
Louis-Philippe Boulet
Keyword(s):  
General Education ◽  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Significant Proportion ◽  
Medication Use ◽  
Dry Powder Inhaler ◽  
Asthma Patient ◽  
Dose Inhaler ◽  
Uncontrolled Asthma ◽  
Asthma Patients

BACKGROUND: Oropharyngeal (OP) symptoms are common in asthma patients using inhaled corticosteroids (ICSs) alone and in combination with a long-acting beta2-agonist (LABA). Patterns of medication use, level of asthma control and association with OP symptoms are not often reported in a nonstudy setting.OBJECTIVES: To determine the prevalence of OP symptoms among adult asthma patients using ICSs alone and an ICS plus a LABA; to investigate the relationships between medication use, asthma control and OP symptoms; and to assess family physicians’ (FPs’) perceptions of the prevalence and management of OP symptoms.METHODS: A random telephone survey of 1003 asthma patients and 250 FPs treating asthma patients was conducted from February to March 2005 across Canada.RESULTS: Twenty-four per cent of patients experienced OP symptoms; 67% of them spoke to their FPs about the OP symptoms. Thirty-one per cent of patients who experienced OP symptoms stopped or reduced their dose of medication. OP symptoms were reported by 25% of patients using ICSs and 22% using an ICS plus a LABA. The incidence of OP symptoms was not affected by the choice of inhalation device (metered-dose inhaler versus dry powder inhaler) or the use of a spacer. Fifty-eight per cent of patients had uncontrolled asthma; patients achieving a lower level of general education were more likely to have poor control. Patients with uncontrolled asthma were more likely than those with controlled asthma to report OP symptoms (28% versus 18%, respectively; P<0.05). Eighty-nine per cent of FPs had patients who had reported OP symptoms to them. FPs estimated that 15% of their patients experienced OP symptoms and that compliance to treatment worsened in approximately 20% of them.CONCLUSIONS: The prevalence of OP symptoms in asthma patients using ICSs and an ICS plus a LABA is significant. OP symptoms were found to be associated with a reduced patient education level, with a likelihood of reducing or stopping medication, and with a less well-controlled asthma patient. While FPs recognized that a significant proportion of their asthma patients experience OP symptoms and that OP symptoms may affect compliance, they underestimated the prevalence of this problem.

scholarly journals Long-term control medication use and asthma control status among children and adults with asthma

2017 ◽  
Vol 54 (10) ◽  
pp. 1065-1072 ◽  
Author(s):  
Hatice S. Zahran ◽  
Cathy M. Bailey ◽  
Xiaoting Qin ◽  
Carol Johnson
Keyword(s):  
Asthma Control ◽  
Medication Use ◽  
Control Medication

scholarly journals Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

2018 ◽  
Vol 51 (1) ◽  
pp. 1701688 ◽  
Author(s):  
Carin Jorup ◽  
Dan Lythgoe ◽  
Hans Bisgaard
Keyword(s):  
Asthma Control ◽  
Medication Use ◽  
Persistent Asthma ◽  
Severe Exacerbation ◽  
Efficacy And Safety ◽  
Night Time ◽  
Double Blind ◽  
Asthma Control Questionnaire ◽  
End Points ◽  
Similar Treatment

Asthma control is often suboptimal in adolescents, but few studies have evaluated asthma treatments in this population.This post hoc analysis assessed the efficacy and safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) for treatment of persistent asthma in adolescent (age 12–17 years) subgroups within six randomised, double-blind trials. The primary end-point was time to first severe exacerbation. Secondary end-points included number of severe exacerbations, asthma-related symptoms, night-time awakenings, morning peak expiratory flow, forced expiratory volume in 1 s, as-needed medication use and five-item asthma control questionnaire scores.In adolescents (n=1847), BUD/FORM MART was similar to or more effective than comparators across each of the studies in reducing the risk of a first severe exacerbation (hazard ratios (HR) BUD/FORM MART versus comparators 0.15–1.01; pooled HR 0.49, 95% CI 0.34–0.70), with comparable outcomes to the adult subgroups (n=12 197). Similar treatment benefits for BUD/FORM MART were observed for secondary end-points. As-needed medication use was lower with BUD/FORM MART than comparators, and BUD/FORM as-needed use was lower in adolescents than adults. Treatment was well tolerated.This analysis supports the use of BUD/FORM MART in adolescents with persistent asthma, its efficacy and safety being consistent with that reported for adults.

Asthma Medication Prescribing Practices in Pediatric Office Visits

2019 ◽  
Vol 58 (4) ◽  
pp. 395-405
Author(s):  
Sanika Rege ◽  
Abhishek Kavati ◽  
Benjamin Ortiz ◽  
Giselle Mosnaim ◽  
Michael D. Cabana ◽  
...  
Keyword(s):  
Asthma Control ◽  
Medication Use ◽  
International Classification Of Diseases ◽  
The United States ◽  
Cross Sectional Study ◽  
Primary Diagnosis ◽  
Asthma Medication ◽  
Office Visits ◽  
Prescribing Practices ◽  
Cross Sectional

This cross-sectional study examined how asthma control, demographic, and clinical characteristics are associated with the use of asthma medications in pediatric office visits in the United States. Data from the 2012-2015 National Ambulatory Medical Care Survey included patients aged 6 to 17 years, with asthma as a primary diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification, code 493.xx). Descriptive weighted analysis evaluated asthma medication use. Multivariable logistic regression examined characteristics associated with asthma prescribing practices. An estimated 2.5 million pediatric office visits were made annually for asthma. The majority of asthma visits involved males (59.3%), children aged 6 to 11 years (54.8%), and whites (73.6%). Several clinical and demographic characteristics contributed to the variations in overall asthma medication use as well as specific drug classes. Lack of documentation of asthma control and uncontrolled asthma were associated with oral corticosteroid and inhaled corticosteroid use in pediatric asthma patients, but not with overall asthma medication use.

Review of efficacy of ciclesonide for the treatment of asthma in children

2021 ◽  
Vol 42 (6) ◽  
pp. 461-470 ◽  
Author(s):  
Michael Blaiss ◽  
William Berger ◽  
Bradley Chipps ◽  
Vivian Hernandez-Trujillo ◽  
Wanda Phipatanakul ◽  
...  
Keyword(s):  
Lung Function ◽  
Asthma Control ◽  
Active Control ◽  
Rescue Medication ◽  
Medication Use ◽  
Asthma Symptoms ◽  
End Point ◽  
Children With Asthma ◽  
Asthma In Children ◽  
Expiratory Flow

Background: Ciclesonide (CIC) is an inhaled corticosteroid (ICS) approved for the maintenance treatment of asthma in patients ages ≥ 12 years. The prodrug aspect of CIC is associated with a safety profile that may make it ideal for children. Objective: The objective was to summarize efficacy results from the eight phase III, randomized, double-blind, controlled trials in children with asthma conducted during CIC clinical development. Methods: Four trials compared CIC 40, 80, or 160 µg/day with placebo. Two trials compared CIC 160 µg/day with fluticasone propionate 200 µg/day, one trial compared CIC 80 or 160 µg/day with fluticasone 200 µg/day, and one trial compared CIC 160 µg/day with budesonide 400 µg/day. Results: The primary end point was met by at least two CIC doses versus placebo in the trials in which the primary end point was the change from baseline in lung function outcome (forced expiratory volume in 1 second [FEV1] % predicted or morning peak expiratory flow [PEF]). A trial that compared CIC with placebo did not meet the primary end point of superiority in time-to-first severe wheeze exacerbation or lack of improvement. The primary end point of noninferiority to the active control (fluticasone or budesonide) in the change from baseline in a lung function outcome (FEV1, morning PEF, evening PEF) was met with the CIC 160-µg dose in all active control trials. CIC generally demonstrated statistically significant improvements in forced expiratory flow at 25%‐75% of forced vital capacity, asthma symptoms, rescue medication use, and asthma control when compared with placebo and noninferiority for these outcomes compared with fluticasone or budesonide. Conclusion: In children with asthma, once-daily CIC significantly improved large and small airway function, asthma symptoms, and asthma control, and reduced rescue medication use compared with placebo. CIC was comparable with other ICS used to treat asthma in children, which demonstrated its worth for the pediatric population.

Sign in / Sign up

Export Citation Format

Share Document